BNP Paribas Financial Markets’s Rigel Pharmaceuticals RIGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$134K Sell
3,423
-2,832
-45% -$87.3K ﹤0.01% 4393
2026
Q1
$169K Buy
6,255
+4,030
+181% +$135K ﹤0.01% 4126
2025
Q4
$95.3K Sell
2,225
-1,719
-44% -$64.8K ﹤0.01% 4397
2025
Q3
$112K Buy
3,944
+2,056
+109% +$61.5K ﹤0.01% 4241
2025
Q2
$35.4K Sell
1,888
-28,963
-94% -$549K ﹤0.01% 4377
2025
Q1
$555K Sell
30,851
-50
-0.2% -$1.01K ﹤0.01% 3131
2024
Q4
$520K Buy
30,901
+9,893
+47% +$190K ﹤0.01% 3278
2024
Q3
$340K Buy
21,008
+19,391
+1,199% +$228K ﹤0.01% 3019
2024
Q2
$13.3K Sell
1,617
-23,679
-94% -$248K ﹤0.01% 3697
2024
Q1
$374K Buy
25,296
+4,923
+24% +$66.3K ﹤0.01% 2997
2023
Q4
$295K Buy
20,373
+2,591
+15% +$26.5K ﹤0.01% 3069
2023
Q3
$192K Buy
17,782
+13,191
+287% +$159K ﹤0.01% 3109
2023
Q2
$59.2K Sell
4,591
-2,334
-34% -$31.6K ﹤0.01% 3419
2023
Q1
$91.4K Sell
6,925
-3,141
-31% -$49.9K ﹤0.01% 3338
2022
Q4
$151K Buy
10,066
+484
+5% +$4.44K ﹤0.01% 3101
2022
Q3
$113K Buy
9,582
+5,978
+166% +$80.9K ﹤0.01% 3720
2022
Q2
$40.7K Buy
3,604
+2,210
+159% +$44.4K ﹤0.01% 3600
2022
Q1
$41.7K Sell
1,394
-2,060
-60% -$55.8K ﹤0.01% 3589
2021
Q4
$91.5K Buy
3,454
+430
+14% +$13K ﹤0.01% 3621
2021
Q3
$110K Buy
3,024
+2,375
+366% +$93.5K ﹤0.01% 3233
2021
Q2
$28.1K Sell
649
-3,298
-84% -$125K ﹤0.01% 3449
2021
Q1
$135K Buy
3,947
+1,883
+91% +$74.6K ﹤0.01% 3215
2020
Q4
$72.2K Sell
2,064
-2,154
-51% -$62.4K ﹤0.01% 3378
2020
Q3
$101K Buy
4,218
+3,630
+617% +$89.1K ﹤0.01% 3112
2020
Q2
$10.8K Sell
588
-4,584
-89% -$82.5K ﹤0.01% 3676
2020
Q1
$80.7K Buy
5,172
+3,239
+168% +$68.9K ﹤0.01% 3318
2019
Q4
$41.4K Sell
1,933
-742
-28% -$15.3K ﹤0.01% 3739
2019
Q3
$50K Buy
2,675
+819
+44% +$16.9K ﹤0.01% 3477
2019
Q2
$48.4K Sell
1,856
-1,638
-47% -$37K ﹤0.01% 3435
2019
Q1
$89.8K Buy
3,494
+3,097
+780% +$70.8K ﹤0.01% 3183
2018
Q4
$9.12K Sell
397
-478
-55% -$13.5K ﹤0.01% 3383
2018
Q3
$28.1K Hold
875
﹤0.01% 3276
2018
Q2
$24.8K Sell
875
-2,180
-71% -$77.6K ﹤0.01% 3409
2018
Q1
$108K Buy
3,055
+51
+2% +$2.04K ﹤0.01% 3139
2017
Q4
$117K Buy
3,004
+2,058
+218% +$78.3K ﹤0.01% 3222
2017
Q3
$24K Sell
946
-271
-22% -$6.59K ﹤0.01% 3502
2017
Q2
$33.2K Buy
1,217
+780
+178% +$21.3K ﹤0.01% 3393
2017
Q1
$14.5K Buy
437
+276
+171% +$7.03K ﹤0.01% 3102
2016
Q4
$3.84K Sell
161
-490
-75% -$14K ﹤0.01% 3794
2016
Q3
$23.9K Buy
651
+289
+80% +$8.29K ﹤0.01% 2789
2016
Q2
$8.06K Buy
+362
New +$9K ﹤0.01% 3023
2016
Q1
Sell
-1,690
Closed -$51.2K 3005
2015
Q4
$51.2K Sell
1,690
-187
-10% -$5.67K ﹤0.01% 2797
2015
Q3
$46.4K Buy
1,877
+1,144
+156% +$34.1K ﹤0.01% 2921
2015
Q2
$23.5K Buy
733
+526
+254% +$20.1K ﹤0.01% 2944
2015
Q1
$7.39K Buy
+207
New +$5.68K ﹤0.01% 2925
2014
Q4
Sell
-520
Closed -$10.1K 2940
2014
Q3
$10.1K Buy
+520
New +$14.7K ﹤0.01% 3585
2014
Q1
Sell
-113
Closed -$3.22K 3736
2013
Q4
$3.22K Sell
113
-2,266
-95% -$66.5K ﹤0.01% 3379
2013
Q3
$85.2K Sell
2,379
-516
-18% -$18.8K ﹤0.01% 2443
2013
Q2
$96.7K Buy
+2,895
New +$131K ﹤0.01% 2537

Other funds holding RIGL

BNP Paribas Financial Markets's RIGL Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Rigel Pharmaceuticals (RIGL) stake by 45% in Q2 2026, selling an estimated $87.3K and leaving 3,423 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #4393.

BNP Paribas Financial Markets first reported a position in RIGL in Q2 2013 and has held it in 49 quarters since. The position peaked at $555K in Q1 2025. 146 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • BNP Paribas Financial Markets held 3,423 shares of Rigel Pharmaceuticals worth $134K as of Q2 2026.
  • BNP Paribas Financial Markets sold 2,832 Rigel Pharmaceuticals shares in Q2 2026, an estimated $87.3K.
  • Rigel Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4393 holding.
  • BNP Paribas Financial Markets first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • BNP Paribas Financial Markets's Rigel Pharmaceuticals position peaked at $555K in Q1 2025.
  • 146 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.